PF-07248144
Drug timelines are a Plus or Pro feature.
6 regulatory and trial events tracked for PF-07248144, covering 2025-12-01 to 2026-04-16. Get the full timeline:
Most recent: Clinical Trial Update: A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment. [Phase 3]